


Neurizon Therapeutics:

A new horizon in neurodegenerative disease treatment



Science-led. Patient-driven. Globally connected.

Neurizon Therapeutics is an Australian clinical-stage biotechnology company advancing investigational treatment for **Amyotrophic Lateral Sclerosis (ALS)** – also known as **Motor Neurone Disease (MND)**.

Our mission is simple yet meaningful: *To bring forward next-generation treatments that make a real difference in the lives of people affected by neurodegenerative diseases and their loved ones.* We are building more than a biotech company – we are creating a community united by science, compassion, and purpose.

Our Lead ALS Investigational Therapy: NUZ-001

NUZ-001 is an investigational, orally administered therapy designed to address the root causes of ALS, not just its symptoms.

In preclinical studies, NUZ-001 has been shown to cross the blood-brain barrier and reach the central nervous system.

It is hypothesized that NUZ-001 may enhance the neurons natural protein-clearance systems: 'Autophagy' a pathway for clearing large protein aggregates and the 'Proteasomal' system which selectively clears smaller protein aggregates.

Together, these pathways play an important role in maintaining protein balance within neurons, also known as protein homeostasis. Supporting the activity of these systems may assist in the processing and clearance of aggregated and misfolded proteins.

Our Progress So Far

Phase 1 and Open-Label Extension Studies

NUZ-001 has completed a Phase 1 clinical study and subsequent 12-month open-label extension (OLE) in a small cohort of people living with ALS in Australia.

Across the study period, treatment appeared safe and generally well tolerated, with no treatment-related serious adverse events reported.

Top-line findings from the Phase 1 and OLE studies demonstrated encouraging trends across exploratory clinical measures, including survival, functional decline, and respiratory outcomes.

Phase 2/3 HEALEY ALS Platform Trial

NUZ-001 has been accepted as Regimen I within the HEALEY ALS Platform Trial, following regulatory clearance.

Patient enrolment and dosing have now commenced, marking the initiation of the regimen within the platform trial.

Looking Ahead

We have entered a pivotal phase of development as NUZ-001 commenced global clinical evaluation through the HEALEY ALS Platform Trial in the United States.

This milestone marks an important step in advancing our lead program within a rigorous, well-established clinical framework designed to efficiently evaluate potential treatments for ALS.

As we progress, our focus remains on the generation of robust clinical data, continued engagement with investigators and regulatory bodies, and disciplined execution of our development strategy.

Alongside our clinical activities, we will continue to build the scientific understanding of NUZ-001 and explore its broader potential across neurodegenerative diseases.

Our Commitment to the ALS Community

Guided by our purpose and commitment to patients, we remain focused on delivering meaningful, science-driven progress and creating a new horizon in the treatment of neurodegenerative diseases.

Together we can create hope by delivering meaningful progress for people living with ALS.

